Augmentation of host antitumor immunity by low doses of cyclophosphamide and mafosfamide in two animal tumor models View Full Text


Ontology type: schema:ScholarlyArticle     


Article Info

DATE

1989-03

AUTHORS

Thomas Reissmann, Rainer Voegeli, Jörg Pohl, Peter Hilgard

ABSTRACT

By cloning in vitro we have obtained two sublines of the L5222 rat leukemia, one with high (L5222-S) and the other with low (L5222-R) in vivo sensitivities to non-toxic doses of mafosfamide, a stabilized derivative of 4-hydroxy-cyclophosphamide. This sensitivity in vivo was not related to the cytotoxic activity of the drug in vitro. Treatment of rats bearing the L5222-S and of mice transplanted with the MOPC-315 plasmocytoma with low doses of mafosfamide or cyclophosphamide resulted in a high percentage of surviving animals, which were resistant to a subsequent tumor challenge. Viable leukemic cells were needed to establish antitumor immunity, since it was not possible to induce resistance by injection of mitomycin-C-treated, non-viable L5222 cells. The adoptive transfer of spleen cells from animals immune against the L5222-S and the MOPC-315 resulted in resistance of the syngeneic recipients against a rechallenge with tumor cells, provided that the animals were treated with an immunosuppressive dose (100 mg/kg) of cyclophosphamide prior to the spleen cell implantation. In nude mice treatment of the L5222 with low doses of mafosfamide also resulted in surviving animals, however resistance to a second tumor challenge occurred only sporadically. The data presented confirm that therapy with cyclophosphamide or mafosfamide enhances host antitumor immunity but, contrary to previous reports, it could be demonstrated that successful tumor rejection was independent of T cells. More... »

PAGES

179-184

Identifiers

URI

http://scigraph.springernature.com/pub.10.1007/bf00204986

DOI

http://dx.doi.org/10.1007/bf00204986

DIMENSIONS

https://app.dimensions.ai/details/publication/pub.1025873521

PUBMED

https://www.ncbi.nlm.nih.gov/pubmed/2924329


Indexing Status Check whether this publication has been indexed by Scopus and Web Of Science using the SN Indexing Status Tool
Incoming Citations Browse incoming citations for this publication using opencitations.net

JSON-LD is the canonical representation for SciGraph data.

TIP: You can open this SciGraph record using an external JSON-LD service: JSON-LD Playground Google SDTT

[
  {
    "@context": "https://springernature.github.io/scigraph/jsonld/sgcontext.json", 
    "about": [
      {
        "id": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/1107", 
        "inDefinedTermSet": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/", 
        "name": "Immunology", 
        "type": "DefinedTerm"
      }, 
      {
        "id": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/11", 
        "inDefinedTermSet": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/", 
        "name": "Medical and Health Sciences", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Adjuvants, Immunologic", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Animals", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Antigens, Neoplasm", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Clone Cells", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Cyclophosphamide", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Drug Administration Schedule", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Female", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Immunity, Innate", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Immunization, Passive", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Leukemia, Experimental", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Male", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Mice", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Mice, Inbred BALB C", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Mice, Nude", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Neoplasm Transplantation", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Rats", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Rats, Inbred Strains", 
        "type": "DefinedTerm"
      }
    ], 
    "author": [
      {
        "affiliation": {
          "name": [
            "Department of Experimental Cancer Research, Asta Pharma AG, P. O. Box 14 01 29, D-4800, Bielefeld 14, FRG"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Reissmann", 
        "givenName": "Thomas", 
        "id": "sg:person.01340535776.53", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01340535776.53"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "name": [
            "Department of Experimental Cancer Research, Asta Pharma AG, P. O. Box 14 01 29, D-4800, Bielefeld 14, FRG"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Voegeli", 
        "givenName": "Rainer", 
        "id": "sg:person.0633453775.54", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.0633453775.54"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "name": [
            "Department of Experimental Cancer Research, Asta Pharma AG, P. O. Box 14 01 29, D-4800, Bielefeld 14, FRG"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Pohl", 
        "givenName": "J\u00f6rg", 
        "id": "sg:person.0750105001.98", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.0750105001.98"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "name": [
            "Department of Experimental Cancer Research, Asta Pharma AG, P. O. Box 14 01 29, D-4800, Bielefeld 14, FRG"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Hilgard", 
        "givenName": "Peter", 
        "id": "sg:person.01023655171.21", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01023655171.21"
        ], 
        "type": "Person"
      }
    ], 
    "citation": [
      {
        "id": "sg:pub.10.1007/bf01631649", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1000151847", 
          "https://doi.org/10.1007/bf01631649"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1016/s0065-2776(08)60685-9", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1005456489"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1016/0192-0561(85)90016-5", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1009463786"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1016/0192-0561(85)90016-5", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1009463786"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1084/jem.155.1.276", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1012689937"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1016/s0065-230x(08)60846-5", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1022578868"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1016/0192-0561(86)90098-6", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1026508026"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1016/0192-0561(86)90098-6", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1026508026"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "sg:pub.10.1007/bf00205685", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1031449860", 
          "https://doi.org/10.1007/bf00205685"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "sg:pub.10.1007/bf00205685", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1031449860", 
          "https://doi.org/10.1007/bf00205685"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "sg:pub.10.1038/271663a0", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1041761092", 
          "https://doi.org/10.1038/271663a0"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "sg:pub.10.1007/bf00205549", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1046560457", 
          "https://doi.org/10.1007/bf00205549"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "sg:pub.10.1007/bf00205549", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1046560457", 
          "https://doi.org/10.1007/bf00205549"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "sg:pub.10.1038/262077a0", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1053098476", 
          "https://doi.org/10.1038/262077a0"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "sg:pub.10.1007/bf00199832", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1053466732", 
          "https://doi.org/10.1007/bf00199832"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "sg:pub.10.1007/bf00199832", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1053466732", 
          "https://doi.org/10.1007/bf00199832"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1016/0022-1759(83)90303-4", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1053705634"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1016/0022-1759(83)90303-4", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1053705634"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1093/jnci/18.6.769", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1075788095"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://app.dimensions.ai/details/publication/pub.1079465053", 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://app.dimensions.ai/details/publication/pub.1079745935", 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1093/jnci/76.4.745", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1079760047"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1093/jnci/77.6.1255", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1079781898"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://app.dimensions.ai/details/publication/pub.1079848326", 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://app.dimensions.ai/details/publication/pub.1079909305", 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://app.dimensions.ai/details/publication/pub.1080245159", 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://app.dimensions.ai/details/publication/pub.1081599010", 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://app.dimensions.ai/details/publication/pub.1081632263", 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://app.dimensions.ai/details/publication/pub.1082078324", 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://app.dimensions.ai/details/publication/pub.1082165067", 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://app.dimensions.ai/details/publication/pub.1082270364", 
        "type": "CreativeWork"
      }
    ], 
    "datePublished": "1989-03", 
    "datePublishedReg": "1989-03-01", 
    "description": "By cloning in vitro we have obtained two sublines of the L5222 rat leukemia, one with high (L5222-S) and the other with low (L5222-R) in vivo sensitivities to non-toxic doses of mafosfamide, a stabilized derivative of 4-hydroxy-cyclophosphamide. This sensitivity in vivo was not related to the cytotoxic activity of the drug in vitro. Treatment of rats bearing the L5222-S and of mice transplanted with the MOPC-315 plasmocytoma with low doses of mafosfamide or cyclophosphamide resulted in a high percentage of surviving animals, which were resistant to a subsequent tumor challenge. Viable leukemic cells were needed to establish antitumor immunity, since it was not possible to induce resistance by injection of mitomycin-C-treated, non-viable L5222 cells. The adoptive transfer of spleen cells from animals immune against the L5222-S and the MOPC-315 resulted in resistance of the syngeneic recipients against a rechallenge with tumor cells, provided that the animals were treated with an immunosuppressive dose (100 mg/kg) of cyclophosphamide prior to the spleen cell implantation. In nude mice treatment of the L5222 with low doses of mafosfamide also resulted in surviving animals, however resistance to a second tumor challenge occurred only sporadically. The data presented confirm that therapy with cyclophosphamide or mafosfamide enhances host antitumor immunity but, contrary to previous reports, it could be demonstrated that successful tumor rejection was independent of T cells.", 
    "genre": "research_article", 
    "id": "sg:pub.10.1007/bf00204986", 
    "inLanguage": [
      "en"
    ], 
    "isAccessibleForFree": false, 
    "isPartOf": [
      {
        "id": "sg:journal.1096240", 
        "issn": [
          "0340-7004", 
          "1432-0851"
        ], 
        "name": "Cancer Immunology, Immunotherapy", 
        "type": "Periodical"
      }, 
      {
        "issueNumber": "3", 
        "type": "PublicationIssue"
      }, 
      {
        "type": "PublicationVolume", 
        "volumeNumber": "28"
      }
    ], 
    "name": "Augmentation of host antitumor immunity by low doses of cyclophosphamide and mafosfamide in two animal tumor models", 
    "pagination": "179-184", 
    "productId": [
      {
        "name": "readcube_id", 
        "type": "PropertyValue", 
        "value": [
          "7b439e730321861869fefaaf8d770228eaa46844f7b7a07bb1718c1229821cb7"
        ]
      }, 
      {
        "name": "pubmed_id", 
        "type": "PropertyValue", 
        "value": [
          "2924329"
        ]
      }, 
      {
        "name": "nlm_unique_id", 
        "type": "PropertyValue", 
        "value": [
          "8605732"
        ]
      }, 
      {
        "name": "doi", 
        "type": "PropertyValue", 
        "value": [
          "10.1007/bf00204986"
        ]
      }, 
      {
        "name": "dimensions_id", 
        "type": "PropertyValue", 
        "value": [
          "pub.1025873521"
        ]
      }
    ], 
    "sameAs": [
      "https://doi.org/10.1007/bf00204986", 
      "https://app.dimensions.ai/details/publication/pub.1025873521"
    ], 
    "sdDataset": "articles", 
    "sdDatePublished": "2019-04-11T14:00", 
    "sdLicense": "https://scigraph.springernature.com/explorer/license/", 
    "sdPublisher": {
      "name": "Springer Nature - SN SciGraph project", 
      "type": "Organization"
    }, 
    "sdSource": "s3://com-uberresearch-data-dimensions-target-20181106-alternative/cleanup/v134/2549eaecd7973599484d7c17b260dba0a4ecb94b/merge/v9/a6c9fde33151104705d4d7ff012ea9563521a3ce/jats-lookup/v90/0000000371_0000000371/records_130829_00000002.jsonl", 
    "type": "ScholarlyArticle", 
    "url": "http://link.springer.com/10.1007%2FBF00204986"
  }
]
 

Download the RDF metadata as:  json-ld nt turtle xml License info

HOW TO GET THIS DATA PROGRAMMATICALLY:

JSON-LD is a popular format for linked data which is fully compatible with JSON.

curl -H 'Accept: application/ld+json' 'https://scigraph.springernature.com/pub.10.1007/bf00204986'

N-Triples is a line-based linked data format ideal for batch operations.

curl -H 'Accept: application/n-triples' 'https://scigraph.springernature.com/pub.10.1007/bf00204986'

Turtle is a human-readable linked data format.

curl -H 'Accept: text/turtle' 'https://scigraph.springernature.com/pub.10.1007/bf00204986'

RDF/XML is a standard XML format for linked data.

curl -H 'Accept: application/rdf+xml' 'https://scigraph.springernature.com/pub.10.1007/bf00204986'


 

This table displays all metadata directly associated to this object as RDF triples.

234 TRIPLES      21 PREDICATES      71 URIs      38 LITERALS      26 BLANK NODES

Subject Predicate Object
1 sg:pub.10.1007/bf00204986 schema:about N196a5ef589a64b818c6a7a1b7361ca49
2 N1e8109af32334e9999c59de2b3d9359f
3 N2d7ead7d39f74184a079c9304d5c6176
4 N605a674f564b41bfb71f4e136fbcdc45
5 N7e2223d51f324a01a3fe21342f059402
6 N87dd5abca322426db6bc74ae93197f5a
7 N92633b4038844e18911a4813bb0c9f59
8 Na3caea010af54a3a8e4d0b8643df6d31
9 Nb0777967658b458789d5f5683ea4a017
10 Nb5a8b31b4a7a4a9595ba3d1d0ec72b43
11 Nbb204207cca54daaab6282d2e95adc23
12 Nc9b2d86c03a64c99a855c0c0056849ab
13 Ncc99b103d8e1476bb6c8c325b3802f32
14 Nd14a6f04a9544173aa4c94b49aa3fb0c
15 Nd2a9fd857638469480ec24203c1a2ad5
16 Nd3133bf05f00425ba5d56201c9302e92
17 Nf6a794fd964a46f08beb96fa6a120cbf
18 anzsrc-for:11
19 anzsrc-for:1107
20 schema:author Nb87548557f0c41049964723e3f250a86
21 schema:citation sg:pub.10.1007/bf00199832
22 sg:pub.10.1007/bf00205549
23 sg:pub.10.1007/bf00205685
24 sg:pub.10.1007/bf01631649
25 sg:pub.10.1038/262077a0
26 sg:pub.10.1038/271663a0
27 https://app.dimensions.ai/details/publication/pub.1079465053
28 https://app.dimensions.ai/details/publication/pub.1079745935
29 https://app.dimensions.ai/details/publication/pub.1079848326
30 https://app.dimensions.ai/details/publication/pub.1079909305
31 https://app.dimensions.ai/details/publication/pub.1080245159
32 https://app.dimensions.ai/details/publication/pub.1081599010
33 https://app.dimensions.ai/details/publication/pub.1081632263
34 https://app.dimensions.ai/details/publication/pub.1082078324
35 https://app.dimensions.ai/details/publication/pub.1082165067
36 https://app.dimensions.ai/details/publication/pub.1082270364
37 https://doi.org/10.1016/0022-1759(83)90303-4
38 https://doi.org/10.1016/0192-0561(85)90016-5
39 https://doi.org/10.1016/0192-0561(86)90098-6
40 https://doi.org/10.1016/s0065-230x(08)60846-5
41 https://doi.org/10.1016/s0065-2776(08)60685-9
42 https://doi.org/10.1084/jem.155.1.276
43 https://doi.org/10.1093/jnci/18.6.769
44 https://doi.org/10.1093/jnci/76.4.745
45 https://doi.org/10.1093/jnci/77.6.1255
46 schema:datePublished 1989-03
47 schema:datePublishedReg 1989-03-01
48 schema:description By cloning in vitro we have obtained two sublines of the L5222 rat leukemia, one with high (L5222-S) and the other with low (L5222-R) in vivo sensitivities to non-toxic doses of mafosfamide, a stabilized derivative of 4-hydroxy-cyclophosphamide. This sensitivity in vivo was not related to the cytotoxic activity of the drug in vitro. Treatment of rats bearing the L5222-S and of mice transplanted with the MOPC-315 plasmocytoma with low doses of mafosfamide or cyclophosphamide resulted in a high percentage of surviving animals, which were resistant to a subsequent tumor challenge. Viable leukemic cells were needed to establish antitumor immunity, since it was not possible to induce resistance by injection of mitomycin-C-treated, non-viable L5222 cells. The adoptive transfer of spleen cells from animals immune against the L5222-S and the MOPC-315 resulted in resistance of the syngeneic recipients against a rechallenge with tumor cells, provided that the animals were treated with an immunosuppressive dose (100 mg/kg) of cyclophosphamide prior to the spleen cell implantation. In nude mice treatment of the L5222 with low doses of mafosfamide also resulted in surviving animals, however resistance to a second tumor challenge occurred only sporadically. The data presented confirm that therapy with cyclophosphamide or mafosfamide enhances host antitumor immunity but, contrary to previous reports, it could be demonstrated that successful tumor rejection was independent of T cells.
49 schema:genre research_article
50 schema:inLanguage en
51 schema:isAccessibleForFree false
52 schema:isPartOf N431f8b5879b4498e86670ac8104d458d
53 Na55da31286e44a3cb994b7833e1850ba
54 sg:journal.1096240
55 schema:name Augmentation of host antitumor immunity by low doses of cyclophosphamide and mafosfamide in two animal tumor models
56 schema:pagination 179-184
57 schema:productId N026cbdc5788c43059d84e99833a25aef
58 N3fb222bb0e92467d997ee850621201ab
59 Nb5e51e88330d4088a3b0b7b2ef416942
60 Nbe461126eb6d44dabcbcea3d68f01954
61 Nccc5e26253f5417eacee78376e5aaf7a
62 schema:sameAs https://app.dimensions.ai/details/publication/pub.1025873521
63 https://doi.org/10.1007/bf00204986
64 schema:sdDatePublished 2019-04-11T14:00
65 schema:sdLicense https://scigraph.springernature.com/explorer/license/
66 schema:sdPublisher N68ffa669b92143bca774416c06aa316c
67 schema:url http://link.springer.com/10.1007%2FBF00204986
68 sgo:license sg:explorer/license/
69 sgo:sdDataset articles
70 rdf:type schema:ScholarlyArticle
71 N00007e159a8942a297985e0db09b7839 schema:name Department of Experimental Cancer Research, Asta Pharma AG, P. O. Box 14 01 29, D-4800, Bielefeld 14, FRG
72 rdf:type schema:Organization
73 N026cbdc5788c43059d84e99833a25aef schema:name doi
74 schema:value 10.1007/bf00204986
75 rdf:type schema:PropertyValue
76 N196a5ef589a64b818c6a7a1b7361ca49 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
77 schema:name Rats
78 rdf:type schema:DefinedTerm
79 N1e8109af32334e9999c59de2b3d9359f schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
80 schema:name Clone Cells
81 rdf:type schema:DefinedTerm
82 N2d7ead7d39f74184a079c9304d5c6176 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
83 schema:name Male
84 rdf:type schema:DefinedTerm
85 N3fb222bb0e92467d997ee850621201ab schema:name readcube_id
86 schema:value 7b439e730321861869fefaaf8d770228eaa46844f7b7a07bb1718c1229821cb7
87 rdf:type schema:PropertyValue
88 N431f8b5879b4498e86670ac8104d458d schema:volumeNumber 28
89 rdf:type schema:PublicationVolume
90 N605a674f564b41bfb71f4e136fbcdc45 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
91 schema:name Adjuvants, Immunologic
92 rdf:type schema:DefinedTerm
93 N68ffa669b92143bca774416c06aa316c schema:name Springer Nature - SN SciGraph project
94 rdf:type schema:Organization
95 N7e2223d51f324a01a3fe21342f059402 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
96 schema:name Antigens, Neoplasm
97 rdf:type schema:DefinedTerm
98 N809b4ad5095148aa97e7b379b0143491 schema:name Department of Experimental Cancer Research, Asta Pharma AG, P. O. Box 14 01 29, D-4800, Bielefeld 14, FRG
99 rdf:type schema:Organization
100 N87dd5abca322426db6bc74ae93197f5a schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
101 schema:name Mice, Inbred BALB C
102 rdf:type schema:DefinedTerm
103 N8b632088d88f4cb6a7e0299c0d5d93e5 rdf:first sg:person.01023655171.21
104 rdf:rest rdf:nil
105 N92633b4038844e18911a4813bb0c9f59 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
106 schema:name Neoplasm Transplantation
107 rdf:type schema:DefinedTerm
108 Na293b22b142f4362adf3cd6e5d034e36 rdf:first sg:person.0633453775.54
109 rdf:rest Nc631760df61c48629715aabcc024ca17
110 Na3caea010af54a3a8e4d0b8643df6d31 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
111 schema:name Cyclophosphamide
112 rdf:type schema:DefinedTerm
113 Na55da31286e44a3cb994b7833e1850ba schema:issueNumber 3
114 rdf:type schema:PublicationIssue
115 Nb0777967658b458789d5f5683ea4a017 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
116 schema:name Leukemia, Experimental
117 rdf:type schema:DefinedTerm
118 Nb16e929eca104160a75a9fe2e3e5f2b8 schema:name Department of Experimental Cancer Research, Asta Pharma AG, P. O. Box 14 01 29, D-4800, Bielefeld 14, FRG
119 rdf:type schema:Organization
120 Nb5a8b31b4a7a4a9595ba3d1d0ec72b43 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
121 schema:name Animals
122 rdf:type schema:DefinedTerm
123 Nb5e51e88330d4088a3b0b7b2ef416942 schema:name nlm_unique_id
124 schema:value 8605732
125 rdf:type schema:PropertyValue
126 Nb87548557f0c41049964723e3f250a86 rdf:first sg:person.01340535776.53
127 rdf:rest Na293b22b142f4362adf3cd6e5d034e36
128 Nbb204207cca54daaab6282d2e95adc23 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
129 schema:name Immunization, Passive
130 rdf:type schema:DefinedTerm
131 Nbe461126eb6d44dabcbcea3d68f01954 schema:name pubmed_id
132 schema:value 2924329
133 rdf:type schema:PropertyValue
134 Nc631760df61c48629715aabcc024ca17 rdf:first sg:person.0750105001.98
135 rdf:rest N8b632088d88f4cb6a7e0299c0d5d93e5
136 Nc9b2d86c03a64c99a855c0c0056849ab schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
137 schema:name Immunity, Innate
138 rdf:type schema:DefinedTerm
139 Ncc99b103d8e1476bb6c8c325b3802f32 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
140 schema:name Drug Administration Schedule
141 rdf:type schema:DefinedTerm
142 Nccc5e26253f5417eacee78376e5aaf7a schema:name dimensions_id
143 schema:value pub.1025873521
144 rdf:type schema:PropertyValue
145 Nd14a6f04a9544173aa4c94b49aa3fb0c schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
146 schema:name Mice
147 rdf:type schema:DefinedTerm
148 Nd2a9fd857638469480ec24203c1a2ad5 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
149 schema:name Female
150 rdf:type schema:DefinedTerm
151 Nd3133bf05f00425ba5d56201c9302e92 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
152 schema:name Mice, Nude
153 rdf:type schema:DefinedTerm
154 Ndb8863b8322247e5a23b2af15b7abecd schema:name Department of Experimental Cancer Research, Asta Pharma AG, P. O. Box 14 01 29, D-4800, Bielefeld 14, FRG
155 rdf:type schema:Organization
156 Nf6a794fd964a46f08beb96fa6a120cbf schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
157 schema:name Rats, Inbred Strains
158 rdf:type schema:DefinedTerm
159 anzsrc-for:11 schema:inDefinedTermSet anzsrc-for:
160 schema:name Medical and Health Sciences
161 rdf:type schema:DefinedTerm
162 anzsrc-for:1107 schema:inDefinedTermSet anzsrc-for:
163 schema:name Immunology
164 rdf:type schema:DefinedTerm
165 sg:journal.1096240 schema:issn 0340-7004
166 1432-0851
167 schema:name Cancer Immunology, Immunotherapy
168 rdf:type schema:Periodical
169 sg:person.01023655171.21 schema:affiliation N809b4ad5095148aa97e7b379b0143491
170 schema:familyName Hilgard
171 schema:givenName Peter
172 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01023655171.21
173 rdf:type schema:Person
174 sg:person.01340535776.53 schema:affiliation Nb16e929eca104160a75a9fe2e3e5f2b8
175 schema:familyName Reissmann
176 schema:givenName Thomas
177 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01340535776.53
178 rdf:type schema:Person
179 sg:person.0633453775.54 schema:affiliation Ndb8863b8322247e5a23b2af15b7abecd
180 schema:familyName Voegeli
181 schema:givenName Rainer
182 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.0633453775.54
183 rdf:type schema:Person
184 sg:person.0750105001.98 schema:affiliation N00007e159a8942a297985e0db09b7839
185 schema:familyName Pohl
186 schema:givenName Jörg
187 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.0750105001.98
188 rdf:type schema:Person
189 sg:pub.10.1007/bf00199832 schema:sameAs https://app.dimensions.ai/details/publication/pub.1053466732
190 https://doi.org/10.1007/bf00199832
191 rdf:type schema:CreativeWork
192 sg:pub.10.1007/bf00205549 schema:sameAs https://app.dimensions.ai/details/publication/pub.1046560457
193 https://doi.org/10.1007/bf00205549
194 rdf:type schema:CreativeWork
195 sg:pub.10.1007/bf00205685 schema:sameAs https://app.dimensions.ai/details/publication/pub.1031449860
196 https://doi.org/10.1007/bf00205685
197 rdf:type schema:CreativeWork
198 sg:pub.10.1007/bf01631649 schema:sameAs https://app.dimensions.ai/details/publication/pub.1000151847
199 https://doi.org/10.1007/bf01631649
200 rdf:type schema:CreativeWork
201 sg:pub.10.1038/262077a0 schema:sameAs https://app.dimensions.ai/details/publication/pub.1053098476
202 https://doi.org/10.1038/262077a0
203 rdf:type schema:CreativeWork
204 sg:pub.10.1038/271663a0 schema:sameAs https://app.dimensions.ai/details/publication/pub.1041761092
205 https://doi.org/10.1038/271663a0
206 rdf:type schema:CreativeWork
207 https://app.dimensions.ai/details/publication/pub.1079465053 schema:CreativeWork
208 https://app.dimensions.ai/details/publication/pub.1079745935 schema:CreativeWork
209 https://app.dimensions.ai/details/publication/pub.1079848326 schema:CreativeWork
210 https://app.dimensions.ai/details/publication/pub.1079909305 schema:CreativeWork
211 https://app.dimensions.ai/details/publication/pub.1080245159 schema:CreativeWork
212 https://app.dimensions.ai/details/publication/pub.1081599010 schema:CreativeWork
213 https://app.dimensions.ai/details/publication/pub.1081632263 schema:CreativeWork
214 https://app.dimensions.ai/details/publication/pub.1082078324 schema:CreativeWork
215 https://app.dimensions.ai/details/publication/pub.1082165067 schema:CreativeWork
216 https://app.dimensions.ai/details/publication/pub.1082270364 schema:CreativeWork
217 https://doi.org/10.1016/0022-1759(83)90303-4 schema:sameAs https://app.dimensions.ai/details/publication/pub.1053705634
218 rdf:type schema:CreativeWork
219 https://doi.org/10.1016/0192-0561(85)90016-5 schema:sameAs https://app.dimensions.ai/details/publication/pub.1009463786
220 rdf:type schema:CreativeWork
221 https://doi.org/10.1016/0192-0561(86)90098-6 schema:sameAs https://app.dimensions.ai/details/publication/pub.1026508026
222 rdf:type schema:CreativeWork
223 https://doi.org/10.1016/s0065-230x(08)60846-5 schema:sameAs https://app.dimensions.ai/details/publication/pub.1022578868
224 rdf:type schema:CreativeWork
225 https://doi.org/10.1016/s0065-2776(08)60685-9 schema:sameAs https://app.dimensions.ai/details/publication/pub.1005456489
226 rdf:type schema:CreativeWork
227 https://doi.org/10.1084/jem.155.1.276 schema:sameAs https://app.dimensions.ai/details/publication/pub.1012689937
228 rdf:type schema:CreativeWork
229 https://doi.org/10.1093/jnci/18.6.769 schema:sameAs https://app.dimensions.ai/details/publication/pub.1075788095
230 rdf:type schema:CreativeWork
231 https://doi.org/10.1093/jnci/76.4.745 schema:sameAs https://app.dimensions.ai/details/publication/pub.1079760047
232 rdf:type schema:CreativeWork
233 https://doi.org/10.1093/jnci/77.6.1255 schema:sameAs https://app.dimensions.ai/details/publication/pub.1079781898
234 rdf:type schema:CreativeWork
 




Preview window. Press ESC to close (or click here)


...